Compare YRD & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YRD | PMVP |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.4M | 81.3M |
| IPO Year | 2015 | 2020 |
| Metric | YRD | PMVP |
|---|---|---|
| Price | $0.62 | $1.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.20 |
| AVG Volume (30 Days) | 118.2K | ★ 692.2K |
| Earning Date | 09-30-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $426.63 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $1.02 |
| 52 Week High | $6.14 | $1.91 |
| Indicator | YRD | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 33.50 | 42.49 |
| Support Level | N/A | $1.32 |
| Resistance Level | $1.05 | $1.35 |
| Average True Range (ATR) | 0.09 | 0.14 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 39.56 | 7.26 |
Yiren Digital Ltd is an AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. Its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.